Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Inclusion Criteria

• 21-64 years old and healthy;
• Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;
• Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
• Have taken hemp or cannabis (in any form) before and tolerated it well;
• Willing to abstain from consuming dietary supplements/botanical products and citrus juices for the duration of the study;
• Willing to abstain from cannabis/marijuana, hemp, THC- and/or CBD-containing products for several weeks;
• Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day;
• Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day;
• Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study;
• Have the ability to and are willing to comply with the requirements of the study;
• Geographically located within a 40-mile radius of Spokane and have the time to participate and;
• Can read and speak English

Exclusion Criteria

• Under the age of 21 or over the age of 64;
• Any major illness;
• Pregnant or nursing;
• History of allergy or intolerance to cannabis or clopidogrel;
• Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
• Never taken cannabis (in any form) before;
• Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data;
• Currently using or have recently used drugs or other illicit substances for recreational purposes;
• Have used cannabis/marijuana, hemp, THC- and/or CBD-containing products within the last 4 weeks;
• Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or;
• Unable to read and speak English